Tags

Type your tag names separated by a space and hit enter

Relationship between the type of hormone replacement therapy and incidence of breast cancer in Korea.
Climacteric. 2022 Jun 08 [Online ahead of print]C

Abstract

OBJECTIVE

This study aimed to investigate the relationship between hormone replacement therapy (HRT) types and breast cancer (BC) incidence in postmenopausal women in Korea.

METHODS

The nested case-control study used data from the National Health Insurance Service database. Among the women aged ≥50 years who menopaused between 2004 and 2007, BC incidence up to 2017 was analyzed in 36,446 women using or having used HRT for >1 year and in 36,446 women who did not use any HRT for more than 1 year. HRT types and duration were classified into three categories.

RESULTS

BC risk (BCR) decreased with tibolone use for all ages. With HRT initiation in women aged ≥50 years, BCR was lower with tibolone and estrogen-progestogen therapy. HRT for <3 years showed lower BCR with tibolone, while higher BCR was observed with estrogen-only therapy. BCR was lower in women of all ages on HRT for >5 years than in the control group.

CONCLUSIONS

For women in their 50s, tibolone use lowers BCR; for all ages, the use of any HRT for >5 years showed lower BCR in Korea. These divergent results from western countries could be associated with the specific characteristics of BC in Korea.

Authors+Show Affiliations

Department of Obstetrics and Gynecology, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.Department of Obstetrics and Gynecology, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.Department of Policy Research Affairs, National Health Insurance Service Ilsan Hospital, Goyang, Republic of Korea.Department of Obstetrics and Gynecology, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.Department of Obstetrics and Gynecology, National Health Insurance Service Ilsan Hospital, Goyang, Republic of Korea.Department of Obstetrics and Gynecology, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

35674251

Citation

Baek, J K., et al. "Relationship Between the Type of Hormone Replacement Therapy and Incidence of Breast Cancer in Korea." Climacteric : the Journal of the International Menopause Society, 2022, pp. 1-7.
Baek JK, Kim HI, Kang MJ, et al. Relationship between the type of hormone replacement therapy and incidence of breast cancer in Korea. Climacteric. 2022.
Baek, J. K., Kim, H. I., Kang, M. J., Seon, K. E., Kim, E. H., & Seo, S. K. (2022). Relationship between the type of hormone replacement therapy and incidence of breast cancer in Korea. Climacteric : the Journal of the International Menopause Society, 1-7. https://doi.org/10.1080/13697137.2022.2077096
Baek JK, et al. Relationship Between the Type of Hormone Replacement Therapy and Incidence of Breast Cancer in Korea. Climacteric. 2022 Jun 8;1-7. PubMed PMID: 35674251.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Relationship between the type of hormone replacement therapy and incidence of breast cancer in Korea. AU - Baek,J K, AU - Kim,H I, AU - Kang,M J, AU - Seon,K E, AU - Kim,E H, AU - Seo,S K, Y1 - 2022/06/08/ PY - 2022/6/8/entrez PY - 2022/6/9/pubmed PY - 2022/6/9/medline KW - Breast cancer KW - hormone replacement therapy KW - incidence KW - menopause KW - postmenopausal KW - tibolone SP - 1 EP - 7 JF - Climacteric : the journal of the International Menopause Society JO - Climacteric N2 - OBJECTIVE: This study aimed to investigate the relationship between hormone replacement therapy (HRT) types and breast cancer (BC) incidence in postmenopausal women in Korea. METHODS: The nested case-control study used data from the National Health Insurance Service database. Among the women aged ≥50 years who menopaused between 2004 and 2007, BC incidence up to 2017 was analyzed in 36,446 women using or having used HRT for >1 year and in 36,446 women who did not use any HRT for more than 1 year. HRT types and duration were classified into three categories. RESULTS: BC risk (BCR) decreased with tibolone use for all ages. With HRT initiation in women aged ≥50 years, BCR was lower with tibolone and estrogen-progestogen therapy. HRT for <3 years showed lower BCR with tibolone, while higher BCR was observed with estrogen-only therapy. BCR was lower in women of all ages on HRT for >5 years than in the control group. CONCLUSIONS: For women in their 50s, tibolone use lowers BCR; for all ages, the use of any HRT for >5 years showed lower BCR in Korea. These divergent results from western countries could be associated with the specific characteristics of BC in Korea. SN - 1473-0804 UR - https://www.unboundmedicine.com/medline/citation/35674251/Relationship_between_the_type_of_hormone_replacement_therapy_and_incidence_of_breast_cancer_in_Korea. DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.